Evidence map›Paper›PMID 38534103›Full record

ArticleAntimicrobial agents and chemotherapy2024

Jonathan Pham, Russell J Benefield, Natali Baker, Shane Lindblom, Nicholas Canfield, Carlos A Gomez, Mark Fisher

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
6.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. RareIDCases · 2026
    Article
  2. Case Report:Frontiers in medicine · 2026
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Jonathan PhamDepartment of Pathology, University of Utah School of Medicine, Salt Lake City, Utah, USA.
Russell J BenefieldDepartment of Pharmacy, University of Utah Health, Salt Lake City, Utah, USA.ORCID 0000-0002-3235-6285
Natali BakerAssociated Regional and University Pathologists (ARUP) Laboratories, Salt Lake City, Utah, USA.
Shane LindblomAssociated Regional and University Pathologists (ARUP) Laboratories, Salt Lake City, Utah, USA.
Nicholas CanfieldAssociated Regional and University Pathologists (ARUP) Laboratories, Salt Lake City, Utah, USA.
Carlos A GomezDivision of Infectious Diseases, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.ORCID 0000-0001-5486-5710
Mark FisherDepartment of Pathology, University of Utah School of Medicine, Salt Lake City, Utah, USA.
University of Utah · USUniversity Pathologists · USUniversity of Nebraska Medical Center · US

Funding

Paratek Pharmaceuticals
6 · The paper itself

Abstract

Nocardiosis typically requires a prolonged treatment duration of ≥6 months and initial combination therapy with 2-3 antibiotics. First-line regimens for nocardiosis are associated with considerable toxicity; therefore, alternative therapies are needed. Omadacycline is an aminomethylcycline with broad antimicrobial activity whose

Indexed as

Anti-Bacterial AgentsMicrobial Sensitivity TestsNocardiaNocardia InfectionsTetracyclinesHumansAnti-Bacterial AgentsomadacyclineTetracyclinesantimicrobial susceptibilityNocardiaomadacycline

Identifiers

PMID38534103
PMCPMC11064614
OpenAlexW4393233745

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.